|
1
|
Ostrom QT, Gittleman H, Liao P,
Vecchione-Koval T, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and other central nervous
system tumors diagnosed in the United States in 2010-2014. Neuro
Oncol. 19 (Suppl 5):v1–v88. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Delgado-López PD and Corrales-García EM:
Survival in glioblastoma: A review on the impact of treatment
modalities. Clin Transl Oncol. 18:1062–1071. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Weller M, van den Bent M, Tonn JC, Stupp
R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E,
Balana C, Chinot O, et al: European Association for Neuro-Oncology
(EANO) guideline on the diagnosis and treatment of adult astrocytic
and oligodendroglial gliomas. Lancet Oncol. 18:e315–e329.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Stupp R and Roila F: ESMO Guidelines
Working Group. Malignant glioma: ESMO clinical recommendations for
diagnosis, treatment and follow-up. Ann Oncol. 20 (Suppl
4):S126–S128. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Pala A, Karpel-Massler G, Rainer C and
Eric M: Epithelial to Mesenchymal transition and progression of
glioblastoma. In: Clinical Management and Evolving Novel
Therapeutic Strategies for Patients with Brain Tumors. Lichtor T
(ed). InTech, ISBN 978-953-51-1058-3, 2013.
|
|
9
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Lee JK, Joo KM, Lee J, Yoon Y and Nam DH:
Targeting the epithelial to mesenchymal transition in glioblastoma:
The emerging role of MET signaling. Onco Targets Ther. 7:1933–1944.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Iser IC, Lenz G and Wink MR: EMT-like
process in glioblastomas and reactive astrocytes. Neurochem Int.
122:139–143. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Saitoh M: Involvement of partial EMT in
cancer progression. J Biochem. 164:257–264. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21(965)2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pal A, Barrett TF, Paolini R, Parikh A and
Puram SV: Partial EMT in head and neck cancer biology: A spectrum
instead of a switch. Oncogene. 40:5049–5065. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kahlert UD, Joseph JV and Kruyt FAE: EMT-
and MET-related processes in nonepithelial tumors: Importance for
disease progression, prognosis, and therapeutic opportunities. Mol
Oncol. 11:860–877. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Edwards LA, Li A, Berel D, Madany M, Kim
NH, Liu M, Hymowitz M, Uy B, Jung R, Xu M, et al: ZEB1 regulates
glioma stemness through LIF repression. Sci Rep.
7(69)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Madany M, Thomas T and Edwards LA: The
curious case of ZEB1. Discoveries (Craiova). 6(e86)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Siebzehnrubl FA, Silver DJ, Tugertimur B,
Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT,
Kupper MD, Neal D, et al: The ZEB1 pathway links glioblastoma
initiation, invasion and chemoresistance. EMBO Mol Med.
5:1196–1212. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Schwechheimer K, Zhou L and Birchmeier W:
E-cadherin in human brain tumours: Loss of immunoreactivity in
malignant meningiomas. Virchows Arch. 432:163–167. 1998.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Howng SL, Wu CH, Cheng TS, Sy WD, Lin PC,
Wang C and Hong YR: Differential expression of Wnt genes,
beta-catenin and E-cadherin in human brain tumors. Cancer Lett.
183:95–101. 2002.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Camand E, Peglion F, Osmani N, Sanson M
and Etienne-Manneville S: N-cadherin expression level modulates
integrin-mediated polarity and strongly impacts on the speed and
directionality of glial cell migration. J Cell Sci. 125(Pt
4):844–857. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Utsuki S, Sato Y, Oka H, Tsuchiya B,
Suzuki S and Fujii K: Relationship between the expression of E-,
N-cadherins and beta-catenin and tumor grade in astrocytomas. J
Neurooncol. 57:187–192. 2002.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Asano K, Duntsch CD, Zhou Q, Weimar JD,
Bordelon D, Robertson JH and Pourmotabbed T: Correlation of
N-cadherin expression in high grade gliomas with tissue invasion. J
Neurooncol. 70:3–15. 2004.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tian Y, Xie Q, He J, Luo X, Zhou T, Liu Y,
Huang Z, Tian Y, Sun D and Yao K: Radioactive (125)I seeds inhibit
cell growth and epithelial-mesenchymal transition in human
glioblastoma multiforme via a ROS-mediated signaling pathway. BMC
Cancer. 15(1)2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Vandewalle C, van Roy F and Berx G: The
role of the ZEB family of transcription factors in development and
disease. Cell Mol Life Sci. 66:773–787. 2009.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Aigner K, Dampier B, Descovich L, Mikula
M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist
P, et al: The transcription factor ZEB1 (deltaEF1) promotes tumour
cell dedifferentiation by repressing master regulators of
epithelial polarity. Oncogene. 26:6979–6988. 2007.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Eger A, Aigner K, Sonderegger S, Dampier
B, Oehler S, Schreiber M, Berx G, Cano A, Beug H and Foisner R:
DeltaEF1 is a transcriptional repressor of E-cadherin and regulates
epithelial plasticity in breast cancer cells. Oncogene.
24:2375–2385. 2005.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Qi S, Song Y, Peng Y, Wang H, Long H, Yu
X, Li Z, Fang L, Wu A, Luo W, et al: ZEB2 mediates multiple
pathways regulating cell proliferation, migration, invasion, and
apoptosis in glioma. PLoS One. 7(e38842)2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen H, Huang Q, Zhai DZ, Dong J, Wang AD
and Lan Q: CDK1 expression and effects of CDK1 silencing on the
malignant phenotype of glioma cells. Zhonghua Zhong Liu Za Zhi.
29:484–488. 2007.PubMed/NCBI(In Chinese).
|
|
36
|
André S, Kojima S, Yamazaki N, Fink C,
Kaltner H, Kayser K and Gabius HJ: Galectins-1 and -3 and their
ligands in tumor biology. Non-uniform properties in cell-surface
presentation and modulation of adhesion to matrix glycoproteins for
various tumor cell lines, in biodistribution of free and
liposome-bound galectins and in their expression by breast and
colorectal carcinomas with/without metastatic propensity. J Cancer
Res Clin Oncol. 125:461–474. 1999.PubMed/NCBI View Article : Google Scholar
|
